Q32 Bio CFO sells 3,972 shares at $16.56

Q32 Bio Inc. (FIXX) reported that officer Lee Kalowski, CFO and President, had 3,972 shares of common stock sold on 2026-08-25 at $16.56 per share.

Rhea-AI Filing Summary

Q32 Bio Inc. (FIXX) reported that officer Lee Kalowski, CFO and President, had 3,972 shares of common stock sold on 2026-08-25 at $16.56 per share. A footnote states these shares were sold automatically to cover tax withholding obligations on vesting RSUs, not at the officer’s discretion. Following this transaction, Kalowski directly holds 138,471 shares of Q32 Bio common stock.

Insider Trade Summary

Net Seller: 3,972 shares

Net Sell 1 txn

Insider Kalowski Lee

Role CFO and President

Sold 3,972 shs ($66K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	3,972	$16.56	$66K

Holdings After Transaction: Common Stock — 138,471 shares (Direct)

Footnotes (1)

1. F1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

Key Figures

Shares sold: 3,972 shares Sale price per share: $16.56 per share Shares owned after transaction: 138,471 shares

3 metrics

Shares sold 3,972 shares Common Stock sold on 2026-08-25 to cover tax withholding

Sale price per share $16.56 per share Price for the 3,972 common shares sold on 2026-08-25

Shares owned after transaction 138,471 shares Direct common stock holdings of Lee Kalowski after the sale

Key Terms

restricted stock units, tax withholding obligations, open market or private transaction

3 terms

restricted stock units financial

"in connection with the vesting of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold by the Reporting Person to cover tax withholding obligations"

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Q32 Bio Inc. (FIXX) report for Lee Kalowski?

Q32 Bio reported that CFO and President Lee Kalowski had 3,972 shares of common stock sold on 2026-08-25 at $16.56 per share to cover tax withholding on vesting RSUs. The filing notes the sales were automatic and not at his discretion.

How many Q32 Bio (FIXX) shares did Lee Kalowski sell and at what price?

Lee Kalowski had 3,972 shares of Q32 Bio common stock sold at $16.56 per share. A footnote explains the transaction was to satisfy tax withholding obligations related to vesting restricted stock units, and the sales were automatic.

How many Q32 Bio (FIXX) shares does Lee Kalowski hold after this Form 4 transaction?

After the reported transaction, Lee Kalowski directly holds 138,471 shares of Q32 Bio common stock. This figure reflects his direct ownership position as reported following the automatic sale for tax withholding on 3,972 shares.

Was the Q32 Bio (FIXX) insider sale by Lee Kalowski discretionary?

No. A footnote states the 3,972-share sale was required to cover tax withholding obligations from vesting restricted stock units, and that these sales were automatic and not in the discretion of Lee Kalowski.

What role does Lee Kalowski hold at Q32 Bio Inc. (FIXX) in this Form 4?

In this Form 4, Lee Kalowski is identified as an officer of Q32 Bio Inc., serving as CFO and President. The reported transaction relates to his equity compensation in the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 09:02 AM EDT Accepted by SEC EDGAR 08/27/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalowski Lee

(Last) (First) (Middle)

Q32 BIO INC.

830 WINTER STREET

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO and President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2026		S(1)		3,972	D	$16.56	138,471	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

	/s/ Eric Bell, Attorney-in-Fact	08/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)